Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals has submitted a compliance certificate for Q4 FY2026 (ending March 31, 2026) as required under SEBI regulations. The certificate from MCS Share Transfer Agent Limited confirms that the company properly processed all securities received for dematerialization within 15 days. This includes verifying that dematerialized securities were listed on the relevant stock exchanges and that physical share certificates were cancelled with the depository substituted as the registered owner. This is a routine regulatory filing required every quarter to ensure proper handling of share dematerialization.
No direct impact on stock price or shareholder value. This is a standard quarterly compliance filing confirming proper dematerialization procedures are being followed as mandated by SEBI.